EBMT Meeting | Conference

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

April 17th 2024

Belumosudil elicited sustained responses and generated no new safety signals in patients with chronic graft-vs-host disease.

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

April 16th 2024

Itacitinib prophylaxis showed signals for reducing CRS and ICANS following treatment with axicabtagene ciloleucel in patients with B-cell lymphoma.

Simulations Improve CAR T-Cell Therapy Understanding and Administration Confidence

April 15th 2024

Simulation-based education can improve health care professionals’ understanding and confidence regarding the treatment of patients with CAR T-cell therapy.

Orca-T May Be a Suitable Option Over PTCy-Based HSCT in Acute Leukemia and MDS

April 15th 2024

Orca-T demonstrated positive impacts on relapse-free survival and overall survival vs PTCy-based HSCT in acute leukemias and myelodysplastic syndrome.

Orca-T Proves Safe and Effective in Advanced Hematologic Malignancies

April 15th 2024

The regulatory T cell enriched donor cell agent Orca-T was safe and displayed activity in the reduced intensity conditioning setting for patients with advanced hematologic malignancies.

Ruxolitinib Elicits High Responses in Steroid-Refractory aGVHD, Regardless of Organ Involvement

April 18th 2022

The overall response rate achieved with ruxolitinib at day 28 proved to be higher than what was achieved with best available therapy in patients with steroid-refractory acute graft-vs-host disease, irrespective of organ involvement.

Weight-Based Dosing With Narsoplimab Is Recommended in HSCT-TMA

April 7th 2021

Pharmacodynamic and pharmacokinetic modeling of the investigational MASP-2 inhibitor narsoplimab supported a weight-based dosing method for patients with hematopoietic stem cell transplant–associated thrombotic microangiopathy.

Cilta-Cel Demonstrates Durable Responses in Relapsed/Refractory Multiple Myeloma

March 17th 2021

Ciltacabtagene autoleucel has a manageable safety profile at its recommended phase 2 dose, and yielded early, deep, and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

Dr. Majhail on the Importance of Utilizing Social Media in Oncology

March 17th 2021

Navneet Majhail, MD, MS, discusses the importance of utilizing social media in oncology.

Dr. Cutler on the Toxicity Profile of Belumosudil in cGVHD

March 17th 2021

Corey S. Cutler, MD, MPH, FRCPC, discusses the toxicity profile of belumosudil in patients with chronic graft-versus-host disease.

Real-World Data Showcase Favorable Outcomes and Less Toxicity With Axi-Cel in Large B-Cell Lymphoma

March 17th 2021

The real-world utilization of axicabtagene ciloleucel demonstrated favorable outcomes and less frequent toxicity events compared with those reported in the pivotal ZUMA-1 trial and other real-world studies.

Dr. Cutler on the Efficacy Results of the ROCKstar Study in cGVHD

March 16th 2021

Corey S. Cutler, MD, MPH, FRCPC, discusses ​the efficacy results of the ongoing phase 2 ROCKstar trial in patients with chronic graft-versus-host disease.

Dr. Giralt on the Potential Utility of Omidubicel in Hematologic Malignancies

March 16th 2021

Sergio A. Giralt, MD, discusses the potential utility of omidubicel in hematologic malignancies.

Liso-Cel Administration in Relapsed/Refractory LBCL Successful in Inpatient, Outpatient Settings at Nonuniversity Centers

March 16th 2021

Lisocabtagene maraleucel was successfully administered in patients with relapsed/refractory aggressive large B-cell lymphoma who were at nonuniversity medical centers in both the outpatient and inpatient settings through the use of standard operating procedures and multidisciplinary teams

Ruxolitinib Induces Prolonged Efficacy in Steroid-Refractory Acute GVHD

March 16th 2021

Ruxolitinib has demonstrated sustained efficacy with a lower probability of progression or additional systemic therapeutics in patients with steroid-refractory acute graft-versus-host disease.

Frontline Axi-Cel Elicits 74% CR Rate in High-Risk Large B-Cell Lymphoma

March 15th 2021

Axicabtagene ciloleucel elicited a high objective response rate of 85%, with a complete response rate of 74% when used as a first-line therapy in patients with high-risk large B-cell lymphoma.

Risk-Adapted CAR T Dosing Maintains Efficacy, Improves Safety in Pediatric Relapsed/Refractory ALL

March 15th 2021

A risk-adapted CD19 CAR T-cell therapy dosing approach allowed pediatric patients with relapsed/refractory acute lymphocytic leukemia to maintain a high rate of remission, while reducing the risk of severe toxicities among those with a high initial disease burden

Dr. Kröger on Long-Term Results With Tandem Transplant in Multiple Myeloma

March 15th 2021

Nicolaus Kröger, MD, discusses the long-term results of a phase 2 study in multiple myeloma.

Dr. Giralt on Omidubicel Vs Standard Umbilical Cord Blood Transplant in Hematologic Malignancies

March 15th 2021

Sergio A. Giralt, MD, discusses the results of a phase 3 trial comparing omidubicel with standard umbilical cord blood transplant in hematologic malignancies.

Brexucabtagene Autoleucel Displays Continued Durability, Safety in Relapsed/Refractory MCL

March 15th 2021

Brexucabtagene autoleucel displayed significant and durable responses and a reduction in adverse effects in patients with relapsed/refractory mantle cell lymphoma.